Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
Globe Newswire•15/10/2026•08:00 ET
0
Key Highlights
- ➤RESOLVE Phase 2b enrollment reached 120 patients on October 12, 2026
- ➤Sample-size reviews confirmed no enrollment increase is required
- ➤Over 3,000 injections completed with no treatment-related serious adverse events
- ➤Phase 2b interim analysis remains on track for December 2026
Expert Statements
James Helliwell, Chief Executive Officer of Eupraxia Pharmaceuticals
“This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE”
James Helliwell, Chief Executive Officer of Eupraxia Pharmaceuticals
“We look forward to our interim analysis in December where we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months. Data will also be available on the patients at 3, 9- and 12-month timepoints giving a fulsome interim look at the RESOLVE Trial”
Jeymi Tambiah, Chief Medical Officer of Eupraxia Pharmaceuticals
“We’re very encouraged by the blinded safety data that we have seen in the Phase 1b/2a and Phase 2b study to date”
Jeymi Tambiah, Chief Medical Officer of Eupraxia Pharmaceuticals
“The tolerability of the injection procedure, and of the drug, will be an important factor in determining how EP-104GI may be adopted by both patients and treating physicians if approved by the FDA. With over 3,000 injections completed and many patients having now been followed for 52 weeks, EP-104GI has been generally well-tolerated, and there have been no treatment-related SAEs to date.”
* Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial
* The Company has a statistical team who are doing periodic reviews of the unblinded data to ensure that the statistical assumptions and sample size on efficacy are adequate and do not need to be revised. These reviews have confirmed that the sample size as designed does not need to be adjusted
Get started
Create a free account to read the full story.